Optic neuropathy diseases refer to a broad category of diseases that cause retinal ganglion cells and their axons to be damaged, including glaucoma, ischemic optic neuropathy, optic neuritis, hereditary optic neuropathy, etc. Most of the etiologies are complex, and some patients have no obvious improvement or even continuous deterioration even after treatment. For example, 20 to 27 percent of glaucoma patients are still becoming blind in one eye and 9 percent in both eyes after the treatment of lower intraocular pressure(IOP).

The death of retinal ganglion cells caused by the diseases is the main cause of visual impairment and blindness in patients. At present, there are no effective drugs targeting to protext the optic nerve.

Neurophth is committed to the development of candidate drugs for optic neuroprotective gene therapy (NFS- 04). The strategy is to use AAV vector to deliver optic neuroprotective genes to retinal RGC cells to reduce the damage of ganglion cells and prevent the death of ganglion cells, thereby protecting and improving visual function.